Following demonstration that subjects could discern between placebo and oxycodone , 24 eligible male and female subjects were randomized to receive intravenous injections of 0.07 mg/kg oxycodone ( OXY ) , 0.07 mg/kg oxycodone and 0.035 mg/kg naloxone solution ( sOXN ) , or matching placebo over three visits .